Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Transcatheter Mitral Valve-in-Valve—A Plausible Option but Questions Remain

Transcatheter Mitral Valve-in-Valve—A Plausible Option but Questions Remain One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve Original Investigation Research Invited Commentary Transcatheter Mitral Valve-in-Valve— A Plausible Option but Questions Remain Anita W. Asgar, MD, MSc It is a mistake to look too far ahead. Only one link in the chain the Kansas City Cardiomyopathy Questionnaire and was sus- of destiny can be handled at a time. tained at 1 year. The data are compelling, leading the authors Winston Churchill to conclude that transcatheter MViV should be considered an Structural valve deterioration is a long-term complication of option for most patients with failed surgical bioprostheses. valve replacement and one that occurs more frequently with An option, certainly, but one that requires careful delibera- tion since many questions remain. biologic valves. Reoperation for structural valve deteriora- tion of a mitral prosthesis is associated with increased mortality, postoperative Remaining Issues complications, and resource The first large experience with transcatheter valve-in-valve Related article page 1245 use. Transcatheter valve-in- therapy came from the treatment of degenerated biopros- valve replacement has shown promise in previously pub- thetic aortic valves. The data collected in the Valve-in-Valve lished series of fewer than 100 patients. It is therefore very International Data registry http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Transcatheter Mitral Valve-in-Valve—A Plausible Option but Questions Remain

JAMA Cardiology , Volume 5 (11) – Nov 29, 2020

Loading next page...
 
/lp/american-medical-association/transcatheter-mitral-valve-in-valve-a-plausible-option-but-questions-lpIKmPTi0T
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2020.2993
Publisher site
See Article on Publisher Site

Abstract

One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve Original Investigation Research Invited Commentary Transcatheter Mitral Valve-in-Valve— A Plausible Option but Questions Remain Anita W. Asgar, MD, MSc It is a mistake to look too far ahead. Only one link in the chain the Kansas City Cardiomyopathy Questionnaire and was sus- of destiny can be handled at a time. tained at 1 year. The data are compelling, leading the authors Winston Churchill to conclude that transcatheter MViV should be considered an Structural valve deterioration is a long-term complication of option for most patients with failed surgical bioprostheses. valve replacement and one that occurs more frequently with An option, certainly, but one that requires careful delibera- tion since many questions remain. biologic valves. Reoperation for structural valve deteriora- tion of a mitral prosthesis is associated with increased mortality, postoperative Remaining Issues complications, and resource The first large experience with transcatheter valve-in-valve Related article page 1245 use. Transcatheter valve-in- therapy came from the treatment of degenerated biopros- valve replacement has shown promise in previously pub- thetic aortic valves. The data collected in the Valve-in-Valve lished series of fewer than 100 patients. It is therefore very International Data registry

Journal

JAMA CardiologyAmerican Medical Association

Published: Nov 29, 2020

References